Artificial Intelligence

Tabia Health's AI platform is now a qualified solution on Mayo Clinic Platform, a move set to automate patient care and reduce clinician burden.

As burnout plagues radiology, Fujifilm unveils AI workflow solutions at HIMSS 2026 aimed at easing workloads and boosting hospital efficiency.

With book value soaring, Stack Capital offers a rare public window into the massive valuations of private titans like SpaceX and the AI infrastructure boom.

AI firm YXT.com lands on a top innovation list with tech giants, but can its cutting-edge training solutions navigate a complex market and redefine work?

Starton Therapeutics files patents to combine its continuous low-dose therapy, STAR-LLD, with CAR-T, aiming to enhance cancer-killing power and durability.

Iconic Australian bootmaker R.M.Williams expands its partnership with Bamboo Rose, leveraging AI-powered planning to modernize its global operations.

A new partnership sees Veritone's AI unlock The Washington Post's video vault, aiming to monetize history while protecting journalistic integrity.

AI drug discovery firm Proxima appoints three titans of science to its board, signaling a major push in proximity therapeutics to rewrite medicine's rules.

A new report reveals why distributors are holding more stock, risking cash flow to battle volatility and win customers in a fiercely competitive market.

New study shows an AI platform matches expert radiologists in tumor measurement, promising a new era of precision and consistency in breast cancer surgery.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

Beating Wall Street estimates with historic gross profits, the chipmaker leverages new capital and key partnerships to push its ultra-low-power tech deeper into AI.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With a new outpatient model, NexCure aims to bring life-saving cancer treatments like CAR-T closer to home, tackling a major healthcare bottleneck.

Investors eye Moody's CEO Rob Fauber's upcoming speech for insights on AI strategy, M&A forecasts, and navigating an increasingly complex global economy.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Syntax Data launches Saidee, an AI that builds custom portfolios using proprietary, traceable data, aiming to solve key compliance fears for financial advisors.